Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 8;21(3):1128.
doi: 10.3390/ijms21031128.

Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?

Davide Angeli  1 , Samanta Salvi  2 , Gianluca Tedaldi  2
Affiliations
Review

Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?

Davide Angeli et al. Int J Mol Sci. .

Abstract

Breast and ovarian cancers are some of the most common tumors in females, and the genetic predisposition is emerging as one of the key risk factors in the development of these two malignancies. BRCA1 and BRCA2 are the best-known genes associated with hereditary breast and ovarian cancer. However, recent advances in molecular techniques, Next-Generation Sequencing in particular, have led to the identification of many new genes involved in the predisposition to breast and/or ovarian cancer, with different penetrance estimates. TP53, PTEN, STK11, and CDH1 have been identified as high penetrance genes for the risk of breast/ovarian cancers. Besides them, PALB2, BRIP1, ATM, CHEK2, BARD1, NBN, NF1, RAD51C, RAD51D and mismatch repair genes have been recognized as moderate and low penetrance genes, along with other genes encoding proteins involved in the same pathways, possibly associated with breast/ovarian cancer risk. In this review, we summarize the past and more recent findings in the field of cancer predisposition genes, with insights into the role of the encoded proteins and the associated genetic disorders. Furthermore, we discuss the possible clinical utility of genetic testing in terms of prevention protocols and therapeutic approaches.

Keywords: cancer predisposition; cancer risk; gene panels; hereditary breast and ovarian cancer; next-generation sequencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Ruddy K.J., Winer E.P. Male breast cancer: Risk factors, biology, diagnosis, treatment, and survivorship. Ann. Oncol. 2013;24:1434–1443. doi: 10.1093/annonc/mdt025. - DOI - PubMed
    1. Ottini L. Male breast cancer: A rare disease that might uncover underlying pathways of breast cancer. Nat. Rev. Cancer. 2014;14:643. doi: 10.1038/nrc3806. - DOI - PubMed
    1. Rizzolo P., Zelli V., Silvestri V., Valentini V., Zanna I., Bianchi S., Masala G., Spinelli A.M., Tibiletti M.G., Russo A., et al. Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy. Int. J. Cancer. 2019;145:390–400. doi: 10.1002/ijc.32106. - DOI - PubMed
    1. Gage M., Wattendorf D., Henry L.R. Translational advances regarding hereditary breast cancer syndromes. J. Surg. Oncol. 2012;105:444–451. doi: 10.1002/jso.21856. - DOI - PubMed

MeSH terms

Substances